Fast Five Quiz: Exudative Age-Related Macular Degeneration (Wet AMD) Intravitreal Injection

F. Ryan Prall, MD


March 01, 2021

Age-related macular degeneration (AMD) is a leading cause of age-related blindness worldwide. Global prevalence estimates suggest that approximately 196 million people were living with AMD in 2020; by 2040, it is expected that 288 million will be affected by the disease. AMD leads to irreversible destruction of the macula, resulting in the loss of the sharp, fine-detail, "straight ahead" vision that is required for activities such as reading, driving, recognizing faces, and seeing in color. Exudative or wet AMD, the advanced form of the disease, accounts for only 10% of cases but 90% of the vision loss that is attributed to AMD. Advances in the treatment of exudative AMD, such as intravitreal injections, have the potential to dramatically improve outcomes in this patient population.

How much do you know about intravitreal injection for exudative AMD? Test your knowledge with this quick quiz.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: